AMGN News Alert Amgen Inc (AMGN) 139.85 09/25/2014 22:23:54

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amgen Inc (AMGN) 139.85 $AMGN

Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:27PM CDT
Seattle Genetics, Inc. (SGEN) announced data from a two-year durability analysis of a phase I study on Adcetris for newly diagnosed mature T-cell lymphoma (MTCL).

BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:24PM CDT
The FDA received paragraph IV certification notice pertaining to BioMarin's (BMRN) Kuvan.

Final Glance: Biotechnology companies
AP - Thu Sep 25, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:

Acorda Skyrockets on $525M Civitas Therapeutics Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 4:47PM CDT
Acorda is set to acquire privately-held biopharmaceutical company, Civitas Therapeutics.

Gilead Scores with TAF-based HIV Regimen, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 4:20PM CDT
Gilead's (GILD) TAF- based STR performed well in two late-stage studies.

Watch for Amgen to Potentially Rebound After Falling 1.64% Yesterday
Comtex SmarTrend(R) - Thu Sep 25, 4:14PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $139.40 to a high of $143.03. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $140.02 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

After Yesterday's Decline of 1.64%, Amgen Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 25, 4:13PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $139.40 to a high of $143.03. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $140.02 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Inovio/GeneOne Life Science Collaborate for Ebola Vaccine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 4:00PM CDT
Inovio Pharmaceuticals, Inc. (INO) is collaborating with GeneOne Life Science for the development of a DNA-based Ebola vaccine.

Midday Glance: Biotechnology companies
AP - Thu Sep 25, 12:24PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:

Early Glance: Biotechnology companies
AP - Thu Sep 25, 10:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Research and Markets: Acute Coronary Syndrome - Current and Future Players: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharma, Merck, Pfizer & Sanofi
Business Wire - Thu Sep 25, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghvcj4/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Current and Future Players" report to their offering.

Acute Coronary Syndrome - Current and Future Players: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharma, Merck, Pfizer & Sanofi
M2 - Thu Sep 25, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx7n7r/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Current and Future Players" report to their offering. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing ACS Market. The report identifies and analyses the key companies shaping and driving the global ACS market. The report provides insight into the competitive ACS landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for ACS - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of ACS sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving ACS market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global ACS market landscape? Identify, understand and capitalize Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/lx...harmapoint

'Fast Money' Recap: What Market? The Focus Remains on Apple
at The Street - Thu Sep 25, 4:00AM CDT
The trading panel discussed how low the market can go and whether biotech stocks can continue to move higher.

Bococizumab (PF-04950615) for Acute Coronary Syndrome - Forecast and Market Analysis to 2023
M2 - Thu Sep 25, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tlpf4q/bococizumab) has announced the addition of the "Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" report to their offering. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially. The publisher anticipates that Pfizer's PCSK9 mAb, bococizumab (PF-04950615), will be the third-to-market PCSK9 inhibitor behind Amgen's evolocumab and Sanofi and Regeneron's alirocumab, which The publisher expects are first and second in line for US regulatory approval, respectively. Similar to these other PCSK9 inhibitors, bococizumab is heading into Phase III studies with positive Phase II dosing and LDL-C lowering results. A novel set of LDL-C drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce levels of LDL-C by enhancing the liver's ability to filter LDL-C particles from the circulation. Scope - Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Aricept for the top seven countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology - Pathophysiology - Prognosis - Quality of Life - Symptoms 4 Disease Management - Treatment Overview 5 Competitive Assessment - Strategic Competitor Assessment 6 Unmet Need and Opportunity - Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques - Therapies that Treat Fibrotic Myocardium and Associated Comorbidities - LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients - Antidotes for New Oral Anticoagulants (NOACs) - Blood-Thinning Agents with Significantly Reduced Bleeding Risks 7 Pipeline Assessment - Clinical Trials by Phase and Trial Status - Promising Drugs in Clinical Development 8 Bococizumab (PF-04950615) - Efficacy - Safety - Dosing and Formulation - Potential Clinical Positioning - Potential Commercial Positioning - Pricing and Reimbursement - SWOT Analysis - Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/tl...ococizumab

Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:30PM CDT
Celgene's (CELG) Otezla gained FDA approval for plaque psoriasis.

Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress
PR Newswire - Wed Sep 24, 4:02PM CDT
Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will host a summary webcast of Kyprolis® (carfilzomib) for Injection data presented at the European Society for Medical Oncology (ESMO) 2014 Congress on Monday, Sept. 29, 2014, at 1 p.m. PT. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc., along with clinical investigators, will participate in the call. In addition, they will discuss a summary of feedback received from key opinion leaders and the steps Amgen is taking to develop Kyprolis across all lines of therapy to address unmet needs in patients with multiple myeloma.

Acorda To Buy Civitas, Gains Parkinson's Disease Drug
at Investor's Business Daily - Wed Sep 24, 12:27PM CDT
Acorda Therapeutics (ACOR) stock popped after the biotechnology company agreed to buy privately held Civitas Therapeutics for $525 million, gaining access to drugs in late development used to treat Parkinson's disease. Acorda obtained global rights...

Uptrend Call Working As Amgen Stock Rises 21.3% (AMGN)
Comtex SmarTrend(R) - Wed Sep 24, 11:03AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 4 months, Amgen has returned 21.34% as of today's recent price of $141.29.

Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 24, 10:05AM CDT
Auxilium Pharmaceuticals' (AUXL) shares soared almost 45% on a $2.2 billion acquisition proposal from Endo.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 109

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 77

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 73

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 13

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 57

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 23

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 147

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 50

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading